Imlifidase
As of the edition of 20 October 2026, Imlifidase is an enzyme: marketed, first approved in 2020 (EU); acts on IGHG1, IGHG2 and IGHG3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Enzyme
- Brand name
- Idefirix
- First approved
- 25 August 2020 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Hansa Biopharma
- Registered trials
- 21, 6 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Immune system; Inherited and neonatal; Nervous system; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Imlifidase.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 1 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 12 | 7 | 2 | 3 |
| Phase 3 | 4 | 2 | 1 | 1 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Hansa Biopharma | Applicant and Lead sponsor of trials | 2013 to now |